With ~$17,652,000 in cash, a six month burn rate of ~$4,758,000, annualized to ~$9,516,000, make it a high $11M to pay for Phase III costs, and ongoing trials NEU does not have to partner up for the usual reasons: lack of money. However, to mitigate risks it may.
Either way NEU is in a strong position to strike a great deal if need be, or have no partnership strings snarling a t/o, or dare I dream, bidding war.
OV
PS I think, and thanks to some posters, the previous news may be far more bullish than at first read, especially the single Phase III trial, and the emphasis on dosage control suggests to me efficacy is near-proven with only dosing optimizing still to do.
NEU Price at posting:
9.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)